M&A Deal Summary |
|
|---|---|
| Date | 2015-12-16 |
| Target | Takeda Pharmaceutical Company - Core Respiratory Business |
| Sector | Life Science |
| Buyer(s) | AstraZeneca |
| Sellers(s) | Takeda |
| Deal Type | Divestiture |
| Deal Value | 575M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1992 |
| Sector | Life Science |
| Employees | 83,100 |
| Revenue | 45.8B USD (2023) |
AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. The Company's aim is to improve the health and quality of life of patients around the world through medicines, treatment solutions, and accessibility to healthcare. AstraZeneca is involved in both the research and development (R&D) and manufacturing of drugs to address critical areas of unmet medical need. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 11 of 19 |
| Sector (Life Science) | 9 of 17 |
| Type (Divestiture) | 3 of 4 |
| Country (Japan) | 1 of 1 |
| Year (2015) | 2 of 3 |
| Size (of disclosed) | 12 of 17 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-11-05 |
ZS Pharma
Coppell, Texas, United States ZS Pharma, founded in 2008, is a privately held specialty pharmaceutical company based in Coppell, Texas and Menlo Park, CA. Our core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions. |
Buy | $2.7B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-12-17 |
Acerta Pharma BV
Oss, Netherlands Acerta Pharma is a cancer drug developer with operations in the Netherlands and in California. |
Buy | $4.0B |
| Category | Company |
|---|---|
| Founded | 1781 |
| Sector | Life Science |
| Employees | 47,347 |
| Revenue | 4.03T JPY (2023) |
Takeda is a global biopharmaceutical organization committed to improving the health and well-being of people worldwide. Takeda is dedicated to addressing unmet medical needs through the development of innovative and transformative therapies. The Company's diverse portfolio encompasses a wide range of therapeutic areas, including oncology, gastroenterology, rare diseases, neuroscience, and vaccines. Takeda was originally established in 1781 and is based in Tokyo, Japan.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 6 |
| Sector (Life Science) | 1 of 3 |
| Type (Divestiture) | 1 of 6 |
| Country (Japan) | 1 of 5 |
| Year (2015) | 1 of 1 |
| Size (of disclosed) | 1 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-05-08 |
Inviragen
Fort Collins, Colorado, United States Inviragen is focused on developing vaccines to protect against infectious diseases worldwide. |
Buy | $35M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-01-05 |
Baxalta - Biologics Manufacturing Facility
Brooklyn Park, Minnesota, United States Baxalta - Biologics Manufacturing Facility is a producer of Entyvio® (vedolizumab) and other biologic products. |
Buy | - |
